Market revenue in 2023 | USD 89.1 million |
Market revenue in 2030 | USD 144.2 million |
Growth rate | 7.1% (CAGR from 2023 to 2030) |
Largest segment | Biomarker services |
Fastest growing segment | Genetic Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Genetic Services, Biomarker Services, Microbiology Services, Anatomic Pathology/Histology, Specimen Management & Storage, Special Chemistry Services |
Key market players worldwide | LabConnect, Eurofins Scientific SE, A. P. Moller Maersk A/S ADR, ACM Global, Cerba Research, Synevo Central Labs, Versiti, Cenetron, Ampersand Capital Partners, Pacific Biomarkers, Cirion |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central lab market will help companies and investors design strategic landscapes.
Biomarker services was the largest segment with a revenue share of 38.38% in 2023. Horizon Databook has segmented the Italy central lab market based on genetic services, biomarker services, microbiology services, anatomic pathology/histology, specimen management & storage, special chemistry services covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing geriatric population and rising prevalence of chronic diseases in Italy are some of the key factors driving the market growth. The country has the third oldest population worldwide, with over 23% of Italians being aged 65 and older in 2020.
Furthermore, the average age of the population is around 45.7 years. The country is home to over 60 million residents, making it an attractive destination for various clinical studies. Favorable government initiatives and rising support for undertaking clinical research are further expected to boost market growth over the forecast period.
For instance, Italian Medicines Agency (AIFA) issues clinical trial guidance and GCP compliance measures for trial sponsors & trial partners and supports clinical development in the country. Furthermore, Italy registered about 15,428 clinical studies involving Italian trial sites on clinicaltrials.gov by June 2021, and the number is expected to grow in the near future.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy central lab market , including forecasts for subscribers. This country databook contains high-level insights into Italy central lab market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account